Condition: Parkinson Disease · Parkinson · Idiopathic Parkinson Disease · Sponsor: Neuron23 Inc.
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.
This description comes directly from the study's public registry record.
Fatta B Nahab, MD, FAAN, FANA · 650-228-2527 · clinicaltrials@neuron23.com
Always discuss trial participation with your own doctor first.
| Banner Sun Health Research Institute | Sun City, Arizona, United States | Recruiting |
| University of Arkansas | Little Rock, Arkansas, United States | Recruiting |
| Neuro-Pain Medical Center | Fresno, California, United States | Recruiting |
| University of California, Irvine | Irvine, California, United States | Recruiting |
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
| Esperanza Clinical | Murrieta, California, United States | Recruiting |
| Parkinson's Research Centers of America - Palo Alto | Palo Alto, California, United States | Recruiting |
| Sutter Neuroscience Institute | Sacramento, California, United States | Recruiting |
| University of Colorado - Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Parkinson's Disease and Movement Disorders Center of Boca Raton | Boca Raton, Florida, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Neurology One | Orlando, Florida, United States | Recruiting |
+ 58 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680830